Commentary|Videos|March 18, 2024
AE Management With Neratinib in HER2+ Early Breast Cancer
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5